NCT05236231View on ClinicalTrials.gov

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

May 13, 2022

Study Completion Date

May 14, 2022

Conditions
Healthy
Interventions
DRUG

Macitentan 10 mg

Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.

DRUG

Tadalafil 20 mg

Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.

DRUG

Macitentan 10 mg/Tadalafil 20mg FDC

FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.

Trial Locations (1)

84124

PRAHS, Salt Lake City

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY